Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics"

Bone. 2016 Aug:89:75-76. doi: 10.1016/j.bone.2016.04.027. Epub 2016 Apr 30.

Authors

Erik Fink Eriksen¹, Jacques P Brown²

Affiliations

¹ Department of Clinical Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Norway and Oslo University.
² Laval University, Quebec City, Canada; CHU de Québec (CHUL) Research Centre, Quebec City, Canada.

PMID: 27142587
DOI: 10.1016/j.bone.2016.04.027

No abstract available

Keywords: Concurrent therapy; Denosumab; Osteoporosis; Parathyroid hormone; Teriparatide.

Publication types

Letter
Comment

MeSH terms

Bone Density
Bone Density Conservation Agents*
Cosmetics
Humans
Osteoporosis
Parathyroid Hormone
Teriparatide*

Substances

Bone Density Conservation Agents
Cosmetics
Parathyroid Hormone
Teriparatide